March 19, 2024 7:37am

As it crests toward shore to jump off the board

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!

Never leave an investor uninformed!

 

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in their portfolio for the short-term

I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Tuesday: The pre-open Dow futures are DOWN -0.24% or (-95 points), the S&P futures are DOWN -0.39% or (-20 points) as the Nasdaq futures are DOWN -0.58% or (-97 points)

Stock futures fell Tuesday,

European markets were flat,

Asis Pacific markets declined.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Monday, the Dow closed UP +75.66 points or +0.20%, the S&P closed UP +32.33 points +0.63% while the Nasdaq closed UP +130.27 points or +0.82%

Economic Data Docket:  Building permits month-over-month, February (+2% expected, -0.3% previously); Housing starts, month-over-month, February (+7.4% expected, -14.8% previously)

 

Monday’s night RegMed Investors (RMi) Closing Bell: “a session of cell and gene therapy sector shifting share pricing. As electronic trading including algorithms sell into strength brought-on by Friday’s triple-witching “covering” … https://www.regmedinvestors.com/articles/13377   

 

Q1/24: march – 4 positive and 8 negative closes

  • February – 1 market holiday, 11 positive and 9 negative closes
  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

Yet again, I am passing on forecasting the daily indications is focused on the Fed’s coming guidance on its policy and coming or not “numbers” re interest rates; the aftermarket was weak as the pre-open waits for the all-clear alarm, …  it is still a mix of ups, downs and just unknowns.

 

The BOTTOM LINE: Sentiment seems moderated … also Nasdaq futures are fluctuating to the downside.

  • The Fed is likely to take a lot of the oxygen out of the room this week as they conclude their March meeting on Wednesday afternoon

The remainder of the month’s trading sessions will be critical as the RegMed sector continues earnings’ in LPS (loss-per-share) season, estimates and consensus which set market reaction and will report “runways” and those whose cash positions render their future questionable.

25 (of 35 covered companies) have reported …13 are left to release earnings of my covered group.

 

There is ALWAYS a however, the cell and gene therapy sector is DUE a rebound EVEN if it is due to algorithms and electronic trading RECOGNIZING risk and the oversold!!

I STILL reiterate, “Don't chase the cell and gene therapy sector.” Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

 

On this coming Wednesday, that <market and share pricing> tension will be finally resolve. The US central bank is set to release its latest monetary policy decision and updated economic projections at 2:00 p.m. ET on Wednesday afternoon, with investors looking for an answer to one key question: does the Fed still think it will cut rates three times in 2024?

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.